根据ESI于2024年3月发布的数据，我校高被引论文（Highly Cited Papers）431篇，热点论文（Hot Papers）6篇，见附件：2024年3月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在431篇高被引论文中，临床医学最多（216篇），占比50.12%，分子生物学与遗传学38篇（8.82%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2024.03 |
2024.01 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
1 |
CLINICAL MEDICINE |
216 |
50.12% |
196 |
48.51% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
38 |
8.82% |
35 |
8.66% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
32 |
7.42% |
31 |
7.67% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
32 |
7.42% |
30 |
7.42% |
|
5 |
MATERIALS SCIENCE |
28 |
6.50% |
22 |
5.45% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
17 |
3.94% |
19 |
4.70% |
|
7 |
ENGINEERING |
4 |
0.93% |
4 |
0.99% |
|
8 |
MICROBIOLOGY |
7 |
1.62% |
7 |
1.73% |
|
9 |
CHEMISTRY |
4 |
0.93% |
5 |
1.24% |
|
10 |
PHYSICS |
10 |
2.32% |
9 |
2.23% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
10 |
2.32% |
10 |
2.48% |
|
12 |
IMMUNOLOGY |
8 |
1.86% |
9 |
2.23% |
|
13 |
SOCIAL SCIENCES, GENERAL |
5 |
1.16% |
5 |
1.24% |
|
14 |
COMPUTER SCIENCE |
11 |
2.55% |
12 |
2.97% |
|
15 |
GEOSCIENCES |
1 |
0.23% |
1 |
0.25% |
|
16 |
AGRICULTURAL SCIENCES |
4 |
0.93% |
5 |
1.24% |
|
17 |
MULTIDISCIPLINARY |
1 |
0.23% |
1 |
0.25% |
|
18 |
ENVIRONMENT/ECOLOGY |
3 |
0.70% |
3 |
0.74% |
|
19 |
合计 |
431 |
100.00% |
404 |
100.00% |
|
序号 |
2024年3月我校6篇热点论文标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
SPATIOTEMPORAL TRANSCRIPTOMIC ATLAS OF MOUSE ORGANOGENESIS USING DNA NANOBALL-PATTERNED ARRAYS |
CELL 185 (10): 1777-+ MAY 12 2022 |
10.1016/j.cell.2022.04.003 |
MOLECULAR BIOLOGY & GENETICS |
205 |
|
2 |
TRIAL OF ENDOVASCULAR THERAPY FOR ACUTE ISCHEMIC STROKE WITH LARGE INFARCT |
NEW ENGLAND JOURNAL OF MEDICINE 388 (14): 1272-1283 APR 6 2023 |
10.1056/NEJMoa2213379 |
CLINICAL MEDICINE |
108 |
|
3 |
NETWORK PHARMACOLOGY PREDICTION AND MOLECULAR DOCKING-BASED STRATEGY TO EXPLORE THE POTENTIAL MECHANISM OF HUANGLIAN JIEDU DECOCTION AGAINST SEPSIS |
COMPUTERS IN BIOLOGY AND MEDICINE 144: - MAY 2022 |
10.1016/j.compbiomed.2022.105389 |
COMPUTER SCIENCE |
85 |
|
4 |
ASSOCIATION BETWEEN GUT MICROBIOTA AND PREECLAMPSIA-ECLAMPSIA: A TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY |
BMC MEDICINE 20 (1): - NOV 15 2022 |
10.1186/s12916-022-02657-x |
CLINICAL MEDICINE |
59 |
|
5 |
OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC |
NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023 |
10.1056/NEJMoa2304594 |
CLINICAL MEDICINE |
37 |
|
6 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
14 |
